Block & Leviton is investigating Gossamer Bio Inc. for potential securities law violations after the company’s shares fell more than 75% following news that its Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension failed to meet its primary endpoint. The firm said it may file an action seeking to recover losses on behalf of investors who bought the stock and suffered declines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602231240PRIMZONEFULLFEED9659353) on February 23, 2026, and is solely responsible for the information contained therein.